Graves' Ophthalmopathy Market to Grow at a CAGR of 7.4%

Pune, India - Exactitude Consultancy: The global Graves' Ophthalmopathy (GO) Market is projected to grow at a CAGR of 7.4% over the forecast period. Growing prevalence of Graves' disease, improved recognition of thyroid-associated orbitopathy, and the introduction of biologic and immunomodulatory treatment options significantly contribute to market expansion.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72230

Introduction
Graves' Ophthalmopathy-also known as thyroid eye disease (TED)-is an autoimmune inflammatory disorder affecting the orbit and extraocular muscles. It leads to symptoms such as proptosis, double vision, eyelid retraction, and, in severe cases, vision impairment. Historically managed through steroids, radiotherapy, and surgery, the treatment landscape has shifted dramatically with the introduction of biologic therapies targeting the underlying autoimmune pathways.

Advances in orbital imaging, multidisciplinary management, and emerging targeted therapeutics are transforming patient outcomes and expanding the recognized patient pool worldwide.

Key Takeaways
• The Graves' Ophthalmopathy Market is expected to grow at a CAGR of 7.4% through the forecast period.
• Rising incidence of autoimmune thyroid diseases globally is a key driver.
• Biologic therapies-especially IGF-1R inhibitors-represent major advancements in GO treatment.
• Improved diagnostic imaging such as orbital CT, MRI, and OCT enhances disease staging and early detection.
• Leading players include Horizon Therapeutics (Amgen), Roche, Novartis, Tepezza®, Janssen, Merck, and Bausch + Lomb.

Market Drivers
• Growing global thyroid disorder burden: Increased prevalence of Graves' disease and Hashimoto's thyroiditis.
• Rising awareness and screening: More patients diagnosed earlier by endocrinologists and ophthalmologists.
• Breakthrough biologic therapies: IGF-1R inhibitors (e.g., teprotumumab) dramatically improving outcomes in moderate-to-severe cases.
• Increased access to orbital imaging: CT/MRI enabling accurate staging of inflammatory vs. fibrotic disease.
• Rise in smoking and genetic predisposition: Key risk factors for developing TED.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72230/graves-ophthalmopathy-market

Market Segmentation
By Disease Type / Severity
• Mild Graves' Ophthalmopathy
• Moderate-to-Severe Active Disease
• Severe Vision-Threatening Disease

By Treatment Type
• Pharmacological Treatments
o Corticosteroids
o Immunosuppressants
o Biologic Therapies (IGF-1R inhibitors, Anti-TNF agents)

• Non-Pharmacological Treatments
o Orbital Radiotherapy
o Prism Glasses
o Lubrication & Ocular Surface Management

• Surgical Interventions
o Orbital Decompression
o Eyelid Surgery
o Strabismus Surgery

By End User
• Hospitals
• Specialty Thyroid & Endocrinology Clinics
• Ophthalmology & Oculoplastic Centers
• Ambulatory Surgical Centers
• Research & Academic Institutes

Regional Outlook
North America
Dominates the Graves' Ophthalmopathy market due to early adoption of biologic therapies, advanced diagnostic infrastructure, and high autoimmune thyroid disease prevalence.

Europe
Strong clinical practice guidelines, structured referral pathways, and widespread availability of steroid-sparing therapies support robust market growth.

Asia-Pacific
Fastest-growing region driven by increasing thyroid disorder incidence, rising smoking prevalence in certain countries, and growing access to specialty oculoplastic care in India, China, and Japan.

Latin America & Middle East/Africa
Growth supported by expanding endocrinology and ophthalmology services, though access to biologics remains limited by cost.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72230

Recent Developments
• FDA and other regulatory approvals of novel IGF-1R inhibitors, offering transformational outcomes for TED patients.
• Expansion of clinical trials evaluating new biologics such as anti-IL-6 and anti-TNF agents.
• Integration of AI-based orbital imaging tools to enhance disease staging and treatment planning.
• Increasing availability of minimally invasive orbital decompression techniques.
• Growth of collaborative care models involving endocrinologists, oculoplastic surgeons, and radiologists.

Expert Quote
"Graves' Ophthalmopathy is seeing a paradigm shift in management as biologic therapies redefine treatment possibilities. With rising thyroid disease prevalence and enhanced diagnostic capabilities, the market is poised for sustained growth,"
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy

Future Outlook
The Graves' Ophthalmopathy Market is expected to expand rapidly as biologics become more accessible and early-stage diagnosis improves worldwide. New therapeutic targets, AI-based diagnostics, and minimally invasive surgical innovations will shape the next decade of GO management.

This report is also available in the following languages : Japanese (グレーブス眼症市場), Korean (그레이브스 안과병 시장), Chinese (格雷夫斯眼病市场), French (Marché de l'ophtalmopathie de Graves), German (Markt für Graves-Ophthalmopathie), and Italian (Mercato dell'oftalmopatia di Graves), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72230

Our More Reports:

Primary Progressive Multiple Sclerosis (PPMS) Market
https://exactitudeconsultancy.com/reports/72071/primary-progressive-multiple-sclerosis-ppms-market

Small Fiber Neuropathy Market
https://exactitudeconsultancy.com/reports/72073/small-fiber-neuropathy-market

Spinal Muscular Atrophy Market
https://exactitudeconsultancy.com/reports/72075/spinal-muscular-atrophy-market

Tardive Dyskinesia Market
https://exactitudeconsultancy.com/reports/72077/tardive-dyskinesia-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.